Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-02-25
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 30000000 NOK
Award criteria: Lowest price

Technical requirements: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously published and implemented an open tender competition regarding bone marrow cancer and other indications ("LIS 1807i benmargskreft/øvrige indikasjoner"). The competition included the active ingredients that were in accordance with the tender documentation, annex 3 - the Active Ingredients List.
The patent for Velcade, L01XX32 is cancelled and a new tender competition for the active ingredient Bortezomib is published. There are no other suppliers in the market that can deliver this in the period up until new contracts are established.
Based on this information, LIS intends to extend the contract between the Regioanl Health Authorities (the Contracting Authorities) and Janssen-Cilag AS (the Supplier). This means that the above described contract is extended for 4 months on verbatim contractual terms as those given in the original framework agreement, see points 4.1. and 4.2. Up until new contracts are established by 1.9.2019.
LIS has examined the market situation and is of the opinion that it is not possible to have a new competition, or that another supplier than Janssen-Cilag AS can deliver the product in the contract period. In addition, the situation that has occurred is not the contracting authority´s fault, nor something that the contracting authority could foresee. LIS therefore believes that there are grounds enter into the contract without a competition. Cf. the Public Procurement Regulations § 13-4 first section, letter b,) no. 3.
Unless LIS receives objections within the guarantee period of 10 calendar days, a contract will be entered into.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously published and implemented an open tender competition regarding bone marrow cancer and other indications ("LIS 1807i benmargskreft/øvrige indikasjoner"). The contest was for the active ingredients that were in accordance with the tender documentation, annex 3 - Active Ingredients List.
The patent for Velcade, L01XX32 is cancelled and a new tender competition for the active ingredient Bortezomib is published. There are no other suppliers in the market that can deliver this in the period up until new contracts are established.
Based on this information, LIS intends to extend the contract between the Regioanl Health Authorities (the Contracting Authorities) and Janssen-Cilag AS (the Supplier). This means that the above described contract is extended for 4 months on verbatim contractual terms as those given in the original framework agreement, see points 4.1. and 4.2. Up until new contracts are established by 1.9.2019.
LIS has examined the market situation and is of the opinion that it is not possible to have a new competition, or that another supplier than Janssen-Cilag AS can deliver the product in the contract period. In addition, the situation that has occurred is not the contracting authority´s fault, nor something that the contracting authority could foresee. LIS therefore believes that there are grounds enter into the contract without a competition. Cf. the Public Procurement Regulations § 13-4 first section, letter b,) no. 3.
Unless LIS receives objections within the guarantee period of 10 calendar days, a contract will be entered.


Winner: Janssen-Cilag AS
Award value: 30000000